Abstract: Fragmentation of cell-free DNA molecules is measured and used for various purposes, including determining methylation, e.g., at a particular site of a DNA molecule, at a particular genomic site in a reference genome for a biological sample (e.g., plasma, serum, urine, saliva) of cell-free DNA of a subject, or for a particular region in the reference genome for the biological sample (also just referred to as a sample). Various types of fragmentation measurements can be used, e.g., end motifs and cleavage profiles. Another purpose is determining a fractional concentration of DNA of a particular tissue type (e.g., clinically-relevant DNA). Another purpose is determining a pathology of a subject using a biological sample including cell-free DNA. The cell-free DNA can be of the subject or of a pathogen (e.g., a virus) in the subject's sample. Sites/regions that are hypermethylated, hypomethylated, 5hmC-enriched, and 5hmC-depleted for a particular tissue type can be used.

Abstract: Various applications can use fragmentation patterns related of cell-free DNA, e.g., plasma DNA and serum DNA. For example, the end positions of DNA fragments can be used for various applications. The fragmentation patterns of short and long DNA molecules can be associated with different preferred DNA end positions, referred to as size-tagged preferred ends. In another example, the fragmentation patterns relating to tissue-specific open chromatin regions were analyzed. A classification of a proportional contribution of a particular tissue type can be determined in a mixture of cell-free DNA from different tissue types. Additionally, a property of a particular tissue type can be determined, e.g., whether a sequence imbalance exists in a particular region for a tissue type or whether a pathology exists for the tissue type.

Abstract: Methods and systems described herein involve using long cell-free DNA fragments to analyze a biological sample from a pregnant subject. The status of methylated CpG sites and single nucleotide polymorphisms (SNPs) is often used to analyze DNA fragments of a biological sample. A CpG site and a SNP are typically separated from the nearest CpG site or SNP by hundreds or thousands of base pairs. Finding two or more consecutive CpG sites or SNPs on most cell-free DNA fragments is improbable or impossible. Cell-free DNA fragments longer than 600 bp may include multiple CpG sites and/or SNPs. The presence of multiple CpG sites and/or SNPs on long cell-free DNA fragments may allow for analysis than with short cell-free DNA fragments alone. The long cell-free DNA fragments can be used to identify a tissue of origin and/or to provide information on a fetus in a pregnant female.

Abstract: Size-band analysis is used to determine whether a chromosomal region exhibits a copy number aberration or an epigenetic alteration. Multiple size ranges may be analyzed instead of focusing on specific sizes. By using multiple size ranges instead of specific sizes, methods may analyze more sequence reads and may be able to determine whether a chromosomal region exhibits a copy number aberration even when clinically-relevant DNA may be a low fraction of the biological sample. Using multiple ranges may allow for the use of all sequence reads from a genomic region, rather than a selected subset of reads in the genomic region. The accuracy of analysis may be increased with higher sensitivity at similar or higher specificity. Analysis may include fewer sequencing reads to achieve the same accuracy, resulting in a more efficient process.

Abstract: Cell-free DNA molecules in a mixture of a biological sample can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined. Mixture methylation level(s) can be measured based on one or more amounts of the plurality of cell-free DNA molecules methylated at a set of site(s) of the particular viral genome. The mixture methylation level(s) can be determined in various ways, e.g., as a density of cell-free DNA molecules that are methylated at a site or across multiple sites or regions. The mixture methylation level(s) can be compared to reference methylation level(s), e.g., determined from at least two cohorts of other subjects. The cohorts can have different classifications (including the first condition) associated with the particular viral genome. A first classification of whether the subject has the first condition can be determined based on the comparing.

Abstract: Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The percentage of fetal DNA can be calculated from the same or different data used to determine the cutoff value, and can use a locus where the mother is homozygous and the fetus is heterozygous. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT).

Abstract: An aberration in a fetal genome can be identified by analyzing a sample of fetal and maternal DNA. Classifications of whether an aberration (amplification or deletion) exists in a subchromosomal region are determined using count-based and size-based methods. The count classification and the size classification can be used in combination to determine whether only the fetus or only the mother, or both, have the aberration in the subchromosomal region, thereby avoiding false positives when the mother has the aberration and the fetus does not.

Abstract: Methods of using rifampicin and zidovudine and pharmaceutical compositions comprising the same to inhibit growth of and/or kill Klebsiella pneumoniae, such as antibiotic-resistant Klebsiella pneumoniae.

Abstract: The present invention relates to a wearable device for healthcare and method for using the device. More specifically, the wearable device is worn on a finger for measuring the health data of the user, selected from one or more of heart rate, blood oxygen saturation, heart rate variability. Based on the measured data, the sleep quality can be monitored and recorded. Disorders such as obstructive sleep apnea (OSA), can be detected. The wearable device may include an optical sensor coupled with or embedded in a main body including a visible light emitter, an IR light emitter and a light detector being arranged along a longitudinal direction of the finger. During operation of the wearable device, the heart rate is monitored based on a detected light signal. When the heart rate is higher than an adaptive threshold, both heart rate and blood oxygen saturation are monitored.

Abstract: Methods of using rifampicin and zidovudine and pharmaceutical compositions comprising the same to inhibit growth of and/or kill Klebsiella pneumoniae, such as antibiotic-resistant Klebsiella pneumoniae.

Abstract: A carrier boat for die package flux cleaning, including: a body having at least one pair of substantially parallel sides, the body comprising one or more die package receptacles each oriented at a non-parallel angle relative to the substantially parallel sides of the body such that, when a die package is seated in a die package receptacle of the one or more die package receptacles, a first pair of opposing sides of a die of the die package are substantially perpendicular to the substantially parallel sides,

Abstract: A wearable device for healthcare and a method thereof, wherein the device is worn on a finger for measuring the health data of the user, including but not limited to, the heart rate, blood oxygen saturation, etc. The wearing size of the device is adjustable for different sizes of fingers. In one embodiment, the device includes a main body at least partially worn on a digit of a user; at least one physiological sensor attached to the main body for detecting physiological information; and at least two branches coupled to the main body for holding the digit while reducing the movement of the device. At least a part of at least one branch is changeable such that the wearing size of the device is adjustable for different sizes of digits. In another embodiment, at least a part of at least one branch is movable such that the wearing size of the device is adjustable for different sizes of digits.

Abstract: A testing device and method thereof verifies performance of a non-invasive physiological information detecting device. The testing device incorporates a first layer to modulate one or more electromagnetic signals, e.g., light, emitted from the non-invasive physiological information detecting device in a first predetermined manner and a second layer to process the electromagnetic signal from the first layer such that the modulated signal received at the physiological information detecting device simulates a change in the electromagnetic signal during a real detecting process. In one embodiment, the second layer modulates one or more electromagnetic signals from the first layer in a second predetermined manner, wherein at least one of the first and second layers modulates one kind of the electromagnetic signals.

Abstract: The present document relates to a tester for testing pulse oximeters, wherein the tester is configured for use with a plurality of measuring devices. The tester device may comprise a plurality of light detector sets and a light emitter set, wherein each of the plurality of light detector sets may be used to trigger the light emitter set. Such an arrangement may allow the tester to be used with a transmissive type pulse oximeter as well as with a reflective type pulse oximeter.

Abstract: An apparatus includes a substrate including an identification code on a first side of the substrate and near a perimeter of the substrate. The apparatus includes a stiffener structure attached to the first side of the substrate. The stiffener structure has a cutout in an outer perimeter of the stiffener structure. The stiffener structure is oriented with respect to the substrate to cause the cutout to expose the identification code. The cutout may have a first dimension and a second dimension orthogonal to the first dimension. The first dimension may exceed a corresponding first dimension of the identification code and the second dimension may exceed a corresponding second dimension of the identification code, thereby forming a void region between the identification code and edges of the stiffener structure.

Abstract: The present invention relates to a wearable device for healthcare and method for using the device. More specifically, the wearable device is worn on a finger for measuring the health data of the user, selected from one or more of heart rate, blood oxygen saturation, heart rate variability. Based on the measured data, the sleep quality can be monitored and recorded. Disorders such as obstructive sleep apnea (OSA), can be detected. The wearable device may include an optical sensor coupled with or embedded in a main body including a visible light emitter, an IR light emitter and a light detector being arranged along a longitudinal direction of the finger. During operation of the wearable device, the heart rate is monitored based on a detected light signal. When the heart rate is higher than an adaptive threshold, both heart rate and blood oxygen saturation are monitored.

Abstract: The present invention relates to a wearable device for healthcare and method for using the device. More specifically, the wearable device is worn on a finger for measuring the health data of the user, selected from one or more of heart rate, blood oxygen saturation, heart rate variability. Based on the measured data, the sleep quality can be monitored and recorded. Disorders such as obstructive sleep apnea (OSA), can be detected. The wearable device may include an optical sensor coupled with or embedded in a main body including a visible light emitter, an IR light emitter and a light detector being arranged along a longitudinal direction of the finger. During operation of the wearable device, the heart rate is monitored based on a detected light signal. When the heart rate is higher than an adaptive threshold, both heart rate and blood oxygen saturation are monitored.